Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Onconetix (ONCO) Payables (2023 - 2025)

Historic Payables for Onconetix (ONCO) over the last 3 years, with Q3 2025 value amounting to $2.0 million.

  • Onconetix's Payables fell 8592.02% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 8592.02%. This contributed to the annual value of $13.1 million for FY2024, which is 1205.53% down from last year.
  • As of Q3 2025, Onconetix's Payables stood at $2.0 million, which was down 8592.02% from $11.3 million recorded in Q2 2025.
  • Over the past 5 years, Onconetix's Payables peaked at $16.1 million during Q3 2023, and registered a low of $1.5 million during Q1 2023.
  • In the last 3 years, Onconetix's Payables had a median value of $13.1 million in 2024 and averaged $11.2 million.
  • Its Payables has fluctuated over the past 5 years, first skyrocketed by 87506.54% in 2024, then tumbled by 8592.02% in 2025.
  • Over the past 3 years, Onconetix's Payables (Quarter) stood at $14.9 million in 2023, then decreased by 12.06% to $13.1 million in 2024, then plummeted by 85.02% to $2.0 million in 2025.
  • Its Payables was $2.0 million in Q3 2025, compared to $11.3 million in Q2 2025 and $11.5 million in Q1 2025.